BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences
May 15 2019 - 7:00AM
Business Wire
BELLUS Health Inc. (TSX: BLU) ("BELLUS Health" or the
"Company"), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of chronic cough and other
hypersensitization-related disorders, today announced that Roberto
Bellini, President and Chief Executive Officer of BELLUS Health,
will present a corporate overview of the Company, including an
update on its lead program BLU-5937 for the treatment of chronic
cough, at three upcoming healthcare investor conferences.
Conference Presentation
Details:
Event: UBS 2019 Global Healthcare
Conference
Date/Time: Monday, May 20, 2019 at
3:30 p.m. EDT
Location: New York, NY
Event: Jefferies 2019 Healthcare
Conference
Date/Time: Wednesday, June 5, 2019
at 3:30 p.m. EDT
Location: New York, NY
Event: Raymond James Life Sciences
and MedTech Conference
Date/Time: Wednesday, June 19, 2019
at 8:35 a.m. EDT
Location: New York, NY
Live webcasts from the UBS, Jefferies and Raymond James
conference presentations may be accessed on the Events and
Presentations page under the Investors & News section of BELLUS
Health's website at www.bellushealth.com. Following the events,
archived webcasts and presentations will be available on the
Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's lead
product candidate, BLU-5937, is being developed for the treatment
of chronic cough. BLU-5937, a highly selective P2X3 antagonist, has
the potential to be a best-in-class therapeutic for chronic cough
patients who do not respond to current therapies. In addition to
chronic cough, BLU-5937 may potentially have clinical benefit in
other afferent hypersensitization-related disorders, such as
visceral pain, hypertension, and migraine, among others. BELLUS
Health is currently conducting pre-clinical studies in additional
undisclosed indications.
Chronic cough is classified as a cough lasting more than eight
weeks and is associated with significant adverse physical, social
and psychosocial effects on health and quality-of-life. More than
26 million adults in the United States suffer from chronic cough.
Of these patients, more than 2.6 million have unexplained or
refractory chronic cough lasting for more than a year. There are
currently no approved treatments for refractory chronic cough,
creating a significant unmet medical need.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005163/en/
Investors:BELLUS HealthFrançois
DesjardinsVice-President,
Finance450-680-4525fdesjardins@bellushealth.com
Solebury TroutChad Rubin646-378-2947crubin@soleburytrout.com
Media:Solebury TroutBrad
Miles646-513-3125bmiles@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Aug 2024 to Sep 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Sep 2023 to Sep 2024